Thrombus Aspiration in STEMI Patients With High Thrombus Burden

Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Dec 24, 2019

Keywords

ClinConnect Summary

This clinical trial is investigating the best way to treat patients who have a specific type of heart attack called ST-segment Elevation Myocardial Infarction (STEMI), particularly those who have a significant amount of blood clots in their arteries. The study is comparing two groups of patients: one group will receive a procedure called manual thrombus aspiration (which helps remove the blood clots) during their treatment, while the other group will not. Researchers want to see if using this procedure improves outcomes for these patients.

To be eligible for this trial, participants must be at least 18 years old and diagnosed with STEMI, needing treatment within 12 hours of their symptoms starting. They should also have a high thrombus burden, meaning there is a lot of clot present in their blood vessels. However, people who are in critical condition, have had certain recent treatments, or have serious health issues that could affect their survival are not eligible to participate. If someone joins the trial, they can expect to receive standard care for their heart attack, with the possibility of receiving the additional aspiration treatment. The study is currently recruiting participants, and all volunteers will need to provide informed consent.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years;
• • 2. STEMI patients undergoing primary PCI within 12 hours after the onset of symptoms;
• • 3. High thrombus burden after guidewire passes the lesion (TIMI thrombus grade ≥3);
• • 4. Informed consent must be voluntary;
• Exclusion Criteria:
• • 1. Haemodynamic instability or cardiogenic shock;
• • 2. After thrombolytic therapy;
• • 3. The predicted survival time is less than 6 months due to non-cardiac disease;
• • 4. History of coronary artery bypass grafting;
• • 5. Participate in other researches within 30 days;
• • 6. Preoperative gastrointestinal bleeding or contraindications to dual antiplatelet therapy;
• • 7. Patients were considered unsuitable by other researchers.